EMR posts modest Q2 growth as pricing and demand offset geopolitical headwinds, while backlog strength and orders signal momentum into a stronger second half.
We use Google Analytics to count anonymous page views and understand which content gets read. No ads, no profiles. Decline keeps you on cookieless mode. Details.
High-signal headlines only — macro events, earnings, M&A, regulatory. Listicles and analyst clickbait filtered out by default. Refreshed hourly.
EMR posts modest Q2 growth as pricing and demand offset geopolitical headwinds, while backlog strength and orders signal momentum into a stronger second half.
Engineering and automation solutions company Emerson (NYSE:EMR) missed Wall Street’s revenue expectations in Q1 CY2026 as sales rose 2.9% year on year to $4.56 billion. On the other hand, the company expects next quarter’s revenue to be around $4.80 billion, close to analysts’ estimates. Its non-GAAP profit of $1.54 per share was in line with analysts’ consensus estimates.